Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31336708 | 0.91 | HCRTR1 (0.40) | HCRTR1RAB9APOLBGAALMNA | |
| SCHEMBL31336693 | 0.91 | HCRTR1 (0.48) | HCRTR1RAB9APOLBGAALMNA | |
| SCHEMBL31336590 | 0.89 | HCRTR1 (0.39) | HCRTR1RAB9APOLBGAALMNA | |
| SCHEMBL31336816 | 0.88 | HCRTR1 (0.38) | HCRTR1RAB9APOLBGAALMNA | |
| SCHEMBL31336861 | 0.86 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL31372691 | 0.84 | RAB9A (0.38) | HCRTR1RAB9APOLBGAALMNA | |
| SCHEMBL31336786 | 0.84 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL31336613 | 0.82 | HCRTR1 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL31336784 | 0.81 | HCRTR1 (0.42) | HCRTR1GAAHCRTR2 | |
| SCHEMBL31336733 | 0.81 | HCRTR1 (0.42) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688154-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - Portela & Ca., S.A. (PT) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025023851-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | disclosed |